FIELD: chemistry.
SUBSTANCE: disclosed is a binding protein which is specific to IL-13, having 6CDR sections (three light and three heavy chains). The invention discloses a structure of an antibody based on this protein and a conjugate based on the antibody. The invention describes versions of nucleic acid which codes the antibody or structure, and an expression vector, a replication vector and cells bearing such vectors. Described is a method of producing the protein by culturing cells and proteins obtained using said method. Described are compositions based on versions of the proteins.
EFFECT: invention can be used in medicine to treat and diagnose diseases associated with IL-13 activity which negatively affects health.
50 cl, 23 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
INTERLEUKIN-13-BINDING PROTEINS | 2016 |
|
RU2650767C2 |
INTERLEUKIN-13-BINDING PROTEINS | 2012 |
|
RU2605327C2 |
METHODS AND COMPOSITIONS FOR ASTHMA TREATMENT USING ANTIBODIES AGAINST IL-13 | 2012 |
|
RU2640025C2 |
THERAPEUTIC DLL4-BINDING PROTEINS | 2010 |
|
RU2570639C2 |
HUMAN IL-13 ANTIBODY MOLECULES | 2004 |
|
RU2387667C2 |
IMMUNOGLOBULINS | 2005 |
|
RU2404192C2 |
MONOCLONAL ANTIBODIES AGAINST PROTEIN RGM A AND APPLICATION THEREOF | 2009 |
|
RU2524136C2 |
ANTI-IL-22R-ANTIBODIES | 2017 |
|
RU2758721C2 |
ADVANCED GLYCATION END PRODUCT (RAGE) RECEPTOR ANTIBODIES AND USING THEM | 2009 |
|
RU2518351C2 |
MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN-31 | 2012 |
|
RU2588462C2 |
Authors
Dates
2013-01-20—Published
2007-09-07—Filed